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ABSTRACT A cDNA clone encoding a glycine transporter
has been isolated from rat brain by a combined PCR and
plaque-hybridization strategy. mRNA synthesized from this
clone (designated GLYT1) directs the expression of sodium-
and chloride-dependent, high-affinity uptake of [3H]glycine by
Xenopus oocytes. [3H]Glycine transport mediated by clone
GLYT1 is blocked by sarcosine but is not blocked by methyl-
aminoisobutyric acid or L-alanine, a substrate specificity sim-
ilar to that described for a previously identified glycine-uptake
system called system Gly. In situ hybridization reveals that
GLYT1 is prominently expressed in the cervical spinal cord and
brainstem, two regions of the central nervous system where
glycine is a putative neurotransmitter. GLYT1 is also strongly
expressed in the cerebellum and olfactory bulb and is expressed
at lower levels in other brain regions. The open reading frame
of the GLYT1 cDNA predicts a protein containing 633 amino
acids with a molecular mass of =70 kDa. The primary struc-
ture and hydropathicity profile of GLYT1 protein reveal that
this protein is a member of the sodium- and chloride-dependent
superfamily of transporters that utilize neurotransmitters and
related substances as substrates.
Termination of synaptic activity is thought to occur through
removal of neurotransmitter from the synaptic cleft by ion-
coupled, high-affinity neurotransmitter transport proteins
(neurotransmitter transporters) located in neuronal and glial
plasma membranes. Drugs that block the action of these
transporters can modulate neural function, probably by in-
creasing the duration of neurotransmitter action. Some neu-
rotransmitter transporters, such as those for the monoam-
ines, are the sites of action for clinically important drugs (for
example, antidepressants) (1), as well as drugs of abuse (for
example, cocaine) (2). Other neurotransmitter transporters,
such as those for the inhibitory amino acid y-aminobutyric
acid (GABA), are potential targets for drugs with anticon-
vulsant properties (3). Therefore, an understanding of the
structure and function of neitrotransmitter transporters may
lead to a better understanding of synaptic regulation and
could also provide a rational basis for the development of
additional, more-specific anti-transporter drugs.
The recent isolation ofcDNA clones encoding transporters
for GABA (4), the monoamines norepinephrine, dopamine,
and serotonin (5-10), and a nonneurotransmitter, betaine
(11), has revealed that these carriers comprise a superfamily
of homologous proteins. Predictions of membrane topology
suggest that these transporters all contain =12 membrane-
spanning domains, a structural motif shared by a number of
carriers that, however, share little mutual sequence homol-
ogy. The amino acid-sequence identity between the known
members of the neurotransmitter transporter superfamily
ranges from "-44% for the GABA transporter (GAT1) versus
the norepinephrine transporter (NET1) to =64% for NET1
versus the dopamine transporter (DAT1), indicating that
subfamilies exist within the superfamily. In addition to an
overall homology, members of this superfamily contain sev-
eral regions of sequence identity distributed throughout the
length of the protein. These regions can be used to design
PCR primers which can be employed to clone additional
members of the superfamily from brain and other tissues. In
this paper we report the results of such a cloning approach,
which has yielded a rat brain cDNAt encoding a sodium- and
chloride-dependent high-affinity glycine transporter.
MATERIALS AND METHODS
RNA Isolation and PCR. Total RNA was prepared from C6
glioma cells and rat tissues by the acid guanidinium/phenol
method (12). cDNA was synthesized directly from 5 Mg of
total RNA or mRNA and amplified by the PCR and standard
protocols. The primers chosen for amplification consisted of
a 128-fold degenerate sense primer corresponding to bases
375-394 ofGAT1 with the sequence (5'-- 3') GAG CTC GTC
GAC AAG AAC GG(TCAG) GG(TCAG) GG(TCAG)
GC(TC) TT and a 48-fold degenerate antisense primer cor-
responding to bases 1108-1030 ofGAT1 with the sequence (5'
-* 3') GGG CCC TCT AGA AA (GA)AT CTG (GA)GT
(GAT)GC (GA)GC (AG)TC. The upstream primer corre-
sponds in the GAT1 protein to amino acids 76-82 with the
sequence KNGGGAF, and the downstream primer corre-
sponds to amino acids 287-293 with the sequence DAATQIF.
With these primers the PCR will generate a 677-base-pair (bp)
product from GAT1 mRNA and a 710-bp product from NET1
mRNA. The amplification protocol consisted of a 1-min
denaturation at 94°C, a 4-min annealing at 55°C, and a 2-min
extension at 72°C for 25-30 cycles on a Perkin-Elmer DNA
thermal cycler. A sample of the amplification reaction was
analyzed by agarose gel electrophoresis, and the appropriate
band was gel-purified and subcloned into pBluescript SK(-).
RNA Blot. Two micrograms of mRNA was subjected to
agarose gel/formaldehyde electrophoresis and transferred to
filter paper. The blot was hybridized overnight at 42°C under
high-stringency conditions [50%o formamide/6x standard sa-
line phosphate/EDTA (SSPE; lx SSPE = 0.15 M NaCI/10
mM phosphate, pH 7.4/1 mM EDTA)/5x Denhardt's solu-
tion/salmon sperm DNA at 100 tg/ml]. The final stringency
wash was done in 0.2x standard saline citrate at 65°C for 15
min. The filter was exposed to film for 2-4 days with two
intensifying screens at -70°C.
cDNA Isolation and Sequencing. A AZAP rat brain cDNA
library (13) containing inserts in the 2-4 kilobase-pair (kbp)
Abbreviation: GABA, y--aminobutyric acid.
tThe sequence reported in this paper has been deposited in the
GenBank data base (accession no. M95413).
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FIG. 1. (A) Ethidium bromide-stained agarose gel of the DNA
products generated with described primers and C6 glioma cell cDNA
as template. Arrow denotes a major product of -700 bp. Lanes: 1 and
2, products with C6 glioma cell mRNA as starting material; 3 and 4,
products with C6 glioma cell total RNA; 2 and 4, products with a
2-fold dilution of the respective cDNA mixtures. (B) RNA blot of
mRNA from C6 glioma cells (lane 1), rat liver and kidney (lanes 2 and
3), and rat forebrain and cerebellum (lanes 4 and 5) probed with the
32P-labeled 700-bp PCR product from C6 glioma cells. Arrow denotes
a single transcript of -3.3 kb. A faint band, visible in lane 2 (liver
mRNA) of the original autoradiogram, is difficult to see in this
photograph.
size range was screened with the same random primer-
labeled PCR product used to probe the RNA blot and under
the same hybridization conditions. Six positive clones were
identified. The phagemids were rescued from each clone and
used for further analysis. Dideoxynucleotide DNA sequenc-
ing was done by a combination of nested deletions and primer
walks.
Xenopus Oocyte Expression and Transport Assays. Xenopus
oocytes were defolliculated and maintained in ND96 medi-
um/5% horse serum (14). mRNA was synthesized from 5 ug
of plasmid template and gel-purified on a Sephadex G-50 spin
column. Ten nanograms of mRNA was microinjected into
each oocyte, and the samples were allowed to translate for
4-7 days. Controls consisted of oocytes injected with 50 nl of
water. [3H]Glycine and drugs were added to a total volume
of 50 pl, and uptake assays were done as described (5). Each
data point represents the mean of three to five oocytes.
In Situ Hybridization. Rat brain and cervical spinal cord
were fixed with 4% paraformaldehyde and processed as
described (15). Twenty-five- to 30-tum frozen sections were
prepared in both sagittal and horizontal planes and were
incubated, free-floating, with 35S-labeled antisense RNA
probes. Control sections were probed with 35S-labeled sense
RNA to determine nonspecific hybridization.
Sequence Analysis. DNA and amino acid sequences were
analyzed on a personal computer with the program PCGENE
and on a DEC VAX computer with the Genetics Computer
Group package. Data bases were searched on the National
Center for Biotechnology Information computer with the
program BLAST (16).
RESULTS AND DISCUSSION
Cloning Strategy. C6 glioma cells have been reported to
possess transporters for a variety of neurotransmitters, in-
cluding GABA (17, 18), aspartate (19), glutamate (19), and
glycine (20, 21). We, therefore, chose these cells as a poten-
tial source of additional members of the neurotransmitter-
transporter superfamily. When RNA from C6 cells is ampli-
fied by the PCR with the degenerate primers described in
Materials and Methods, a major product of -700 bp is seen
(Fig. 1A). The nucleotide sequence of this PCR product
encodes a peptide with significant homology to both GAT1
and NET1 proteins (data not shown). RNA blot analysis with
the PCR product as a probe reveals a single transcript of -3.3
kilobases (kb) in C6 cell mRNA and in rat forebrain and
cerebellum mRNA (Fig. 1B). There is a barely detectable
signal in rat liver mRNA and no detectable signal in kidney
mRNA. This result indicated that the gene corresponding to
this PCR product is expressed in brain but is not expressed
(or is expressed at low levels) in nonneural tissue. Therefore,
a size-selected AZAP rat brain cDNA library was screened
with the C6 cell PCR product, and six positive clones were
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FIG. 2. Expression ofGLYT1
in Xenopus oocytes. Assays were
done 4 days after injection of
oocytes with 10 ng ofmRNA or 50
nl ofwater. Each point represents
the mean ± SEM of [3H]glycine
uptake by three to five oocytes.
All assays were done at room
temperature for 1 hr. (A) Uptake
of [3H]GABA, [3H]glycine, [3H]-
glutamic acid, and ,B-[3H]alanine.
Each amino acid was used at a
final concentration of 1 ,uM. (B)
Uptake of [3H]glycine in normal
saline and saline in which sodium
was replaced by lithium (No So-
dium) or saline in which chloride
was replaced by acetate (No
Chloride). (C) Inhibition of [3H]-
glycine uptake by three amino ac-
ids or amino acid analogs. Unla-
beled L-alanine (L-ALA), methyl-
aminobutyric acid (MAIB), or
sarcosine (SARC) was included in
the incubation mixture at a final
concentration of 500 ,M.
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plaque-purified. Partial nucleotide sequences from these
clones indicated that five of the six clones were clearly
related to each other and to the original PCR product,
whereas the sixth represented an unrelated clone. One of
these five clones (clone 9-iB) appeared to be full-length at the
5' end of the open reading frame, and this clone was chosen
for further analysis and expression.
Functional Expression. Oocytes injected with 9-lB mRNA
were tested for their ability to take up radiolabeled neuro-
transmitters or related compounds. Fig. 2A shows that
oocytes expressing clone 9-lB do not significantly accumu-
late [3H]GABA, [3H]glutamate, or /[3H]alanine above back-
ground levels. In contrast, the accumulation of [3H]glycine is
enhanced markedly in oocytes injected with 9-lB RNA,
reaching levels of -10-20 pmol after 1 hr of incubation in 2.5
tkM [3H]glycine. This result indicated that clone 9-lB en-
codes a glycine transporter, and it was designated GLYT1.
Uptake by oocytes injected with GLYT1 mRNA depends
on both extracellular sodium and extracellular chloride,
indicating that the transporter encoded by this clone mediates
ion-coupled active transport of [3H]glycine (Fig. 2B). Inter-
estingly, the moderate level of [3H]glycine uptake by control
oocytes is also sodium- and chloride-dependent, indicating
that Xenopus oocytes possess an endogenous transport sys-
tem for glycine. This fact is not surprising because uptake
systems for metabolically important amino acids are found in
both neural and nonneural tissues (22). Oocytes injected with
GLYT1 mRNA take up [3H]glycine by a high-affinity mech-
anism (Fig. 3 A and B). Kinetic analysis revealed a Km of 33
± 8 uM (mean ± SEM, n = 3), which is similar to the Km
values reported previously for high-affinity glycine uptake in
the central nervous system (23-25). This Km value is almost
3-fold lower than that reported for [3H]glycine uptake by C6
glioma cells (Km = 95 ,IM) (21). The Vm,, value for the cloned
transporter varied, depending on the batch of oocytes, from
120 to 390 pmol per oocyte per hr (mean = 246 ± 78). The
oocyte glycine transporter also appears to be a high-affinity
transporter with a Km of =20 ,uM and a Vma. of =20 pmol per
oocyte per hr (data not shown).
At least three uptake systems able to transport glycine,
termed system Gly, system ASC, and system A, have been
demonstrated in a variety of tissues and cell types by using
amino acids and amino acid analogs as substrates and com-
petitive inhibitors (26). Therefore, the substrate specificity of
GLYT1 was examined by using several of the subtype-
specific compounds (at a final concentration of 500 ,uM) as
competitive inhibitors of [3H]glycine uptake by mRNA-
injected oocytes (Fig. 2C). Sarcosine (N-methylglycine), a
system Gly substrate, inhibits [3H]glycine uptake by oocytes
injected with GLYT1 mRNA by >85%. By contrast, L-ala-
nine, a system ASC substrate, and methylaminoisobutyric
acid, a system A substrate, are almost completely ineffective
as inhibitors. This inhibition profile suggests that GLYT1
represents a system Gly-like transporter, in agreement with
the substrate specificity defined for the native glycine trans-
porter expressed by C6 cells (21). However, the substrate
specificity of GLYT1 differs from that described in earlier
work on the rat spinal cord (23), where sarcosine was
reported to have no significant inhibitory effect at concen-
trations as high as 1 mM. Thus, GLYT1 may represent one
of several glycine-transporter subtypes expressed in brain.
The oocyte endogenous glycine transporter shows an in-
hibition profile different from GLYT1. The former is inhib-
ited almost 90%o by L-alanine (Fig. 2C), L-serine, and L-Cys-
teine (data not shown). This transporter is not blocked by
methylaminoisobutyric acid and is only partially inhibited by
sarcosine (Fig. 2C). Therefore, the endogenous transporter
appears similar to system ASC.
Sequence Analysis. Nucleotide sequencing of the GLYT1
cDNA revealed an open reading frame encoding a protein of
633 amino acids with a molecular mass of 70,570 Da (Fig. 4).
The protein contains four putative N-glycosylation sites
located in a region, which, for GATi, is proposed to form a
large extracellular loop (4). There are five putative protein
kinase C phosphorylation sites. A Kyte-Doolittle analysis of
GLYT1 yielded a hydrophobicity profile almost identical to
that seen for GATi (4) and other members of this transporter
superfamily, suggesting that the membrane topology of
GLYT1 is similar to proposed models (4, 5, 8). Further
analysis with CLUSTAL and PALIGN (PCGENE) showed that
GLYT1 is homologous to all known members of the neuro-
transmitter-transporter superfamily, with identities ranging
from 37% to 41% and overall homologies (identity plus
similarity) of 53% to 61%. A search of the GenBank and
Protein Identification Resource data bases with the program
BLAST did not reveal significant homologies between GLYT1
and any cloned genes other than the known members of this
superfamily.
Cellular Localization. In situ hybridization was used to
study distribution of GLYT1 mRNA in the rat central ner-
vous system (Fig. 5 A-D). There is prominent labeling in all
lamina of the cervical spinal cord, the brainstem nuclei
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FIG. 3. Kinetics of [3H]glycine uptake. Michaelis-Menten (A)
and Eadie-Hofstee (B) plots of [3H]glycine uptake by oocytes
injected with GLYT1. V, velocity; V/S, velocity/substrate. These
values represent the difference between [3H]glycine uptake by
mRNA-injected oocytes and water-injected control oocytes.
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FIG. 4. Amino acid sequence of GLYT1 aligned with the amino acid sequences of GAT1 (4) and NET1 (5). Residues identical among all
three proteins are boxed; residues representing conservative substitutions are shaded. Putative transmembrane regions are denoted by bars,
potential N-glycosylation sites are marked with asterisks, and potential protein kinase C phosphorylation sites are marked by arrowheads.
Alignment was done with the program CLUSTAL in PCGENE.
(including the spinal trigeminal nucleus, Fig. 5A), the cere-
bellum (Fig. 5B), and the olfactory bulb (Fig. SC). Lighter
labeling is present in other medullary, pontine, midbrain,
thalamic, and hypothalamic nuclei (data not shown). Label-
ing above background could not be detected in the cerebral
cortex, caudate-putamen and globus pallidus, hippocampal
formation, or septal nuclei. Furthermore, there is no specific
labeling in white-matter fiber tracts. No specific labeling was
observed in control sections incubated with sense RNA
probes (Fig. SD). Thus, GLYT1 is not expressed in all regions
of the central nervous system. Instead, its expression is
limited to those areas where glycine is thought to function as
a neurotransmitter and to other specific regions where gly-
cine might play a neurotransmitter role.
Labeling in the brain stem (Fig. SA) and cervical spinal cord
is clearly associated with neuronal cell bodies, although hy-
bridization to glial cells cannot be ruled out. Cerebellar label-
ingis confined to the Purkinje cell layer, where the silvergrains
form a continuous band (Fig. 5B). The Purkinje cells them-
selves are not labeled, and labeling does not appear to be
associated with basket, Golgi, or Lugaro cells, which may be
located near the Purkinje cell layer. Instead, the labeling
pattern indicates that GLYT1 is expressed in Bergmann glia,
which are located in this layer. The absence ofGLYT1 mRNA
in the cerebellar Golgi neurons contrasts with previous reports
that, in the rat, these neurons take up [3H]glycine (27) and
contain glycine immunoreactivity (28, 29); thus, this finding
provides further evidence for the possibility of multiple gly-
cine-transporter subtypes. In the olfactory bulb, there is
prominent labeling of many cells located in the glomerular
layer (Fig. 5C). Labeled cells also occur in the external
plexiform layer, the mitral cell body layer, and the granule cell
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FIG. 5. Localization of GLYT1 expression in the rat central
nervous system. (A) Sagittal section through the medulla; numerous
heavily labeled cells appear in the spinal trigeminal nucleus. (B)
Horizontal section through cerebellum showing a band of labeling in
the Purkinje cell layer. ML, molecular cell layer; PCL, Purkinje cell
layer; GCL, granule cell layer; WM, white matter. (C) Horizontal
section through the main olfactory bulb. (D) Control section. Same
as C, except section was incubated with sense mRNA probe. GL,
glomerular layer; EPL, external plexiform layer; MCL, mitral cell
layer; GRL, granule cell layer. (Bar = 200 pm forA and 100 ,m for
B-D.)
layer (Fig. 5C). Although localization of [3H]glycine uptake in
the olfactory bulb is equivocal (30), recent immunocytochem-
ical studies suggest that the periglomerular neurons and some
cells in the granule cell layer contain glycine (29). As in the
other labeled regions, we cannot rule out the possibility that
some glia cells in the olfactory bulb express GLYT1.
Availability of the GLYT1 cDNA should facilitate our
understanding of glycinergic metabolism in the central ner-
vous system. In addition, further in situ hybridization studies
of GLYT1 expression will undoubtedly aid in identifying
putative glycinergic neurons in the spinal cord, the brain-
stem, and in forebrain structures not conventionally associ-
ated with glycinergic neurotransmission.
Note Added in Proof. After this paper was submitted, Smith et al. (31)
reported the isolation of a rat brain glycine transporter cDNA clone
whose sequence and distribution is similar, but not identical, to that
of GLYT1.
We thank M. Quick for oocyte preparation, L. Czyzyk for assis-
tance with nucleotide sequencing, and A. Figl for assistance with
oligonucleotide synthesis. This work was supported by National
Institutes of Health Grant EY04067, Neuroendocrine Anatomy Core
Grant DK4130, and Veterans Administration Medical Research
Funds to N.B.; National Institutes of Health Grant NS-11756 to
H.A.L. and N.D.; and a National Institutes of Health Postdoctoral
Fellowship to J.G.
1. Glowinski, J. & Axelrod, J. (1964) Nature (London) 204,
1318-1319.
2. Horn, A. S. (1990) Prog. Neurobiol. 34, 387-400.
3. Krogsgaard-Larsen, P., Labouta, I. M., Meldrum, B.,
Croucher, M. & Schousboe, A. (1981) in Neurotransmitter,
Seizures and Epilepsy, eds. Morselli, P. L., Loscher, W.,
Lloyd, K. G., Meldrum, B. & Reynolds, E. H. (Raven, New
York), pp. 23-33.
4. Guastella, J., Nelson, N., Nelson, H., Czyzyk, L., Keynan, S.,
Miedel, M. C., Davidson, N., Lester, H. A. & Kanner, B. I.
(1990) Science 249, 1303-1306.
5. Pacholcyzk, T., Blakely, R. D. & Amara, S. G. (1991) Nature
(London) 350, 350-353.
6. Kilty, J. E., Lorange, D. & Amara, S. G. (1991) Science 254,
578-579.
7. Shimada, S., Kitayama, S., Lin, C.-L., Patel, A., Nanthaku-
mar, E., Gregor, P., Kuhar, M. & Uhl, G. (1991) Science 254,
576-578.
8. Usdin, T. B., Mezey, E., Chen, C., Brownstein, M. J. & Hoff-
man, B. J. (1991) Proc. Natl. Acad. Sci. USA 88, 11168-11171.
9. Blakely, R. D., Berson, H. E., Fremeau, R. T., Caron, M. G.,
Peek, M. M., Prince, H. K. & Bradely, C. C. (1991) Nature
(London) 354, 66-70.
10. Hoffman, B. J., Mezey, E. & Brownstein, M. J. (1991) Science
254, 579-580.
11. Yamauchi, A., Uchida, S., Kwon, H. M., Preston, A. S.,
Robey, R. B., Garcia-Perez, A., Burg, M. B. & Handler, J. S.
(1992) J. Biol. Chem. 267, 649-652.
12. Chomczynski, P. & Sacchi, N. (1987) Anal. Biochem. 162,
156-159.
13. Snutch, T. P., Leonard, J. P., Gilbert, M. M., Lester, H. A. &
Davidson, N. (1990) Proc. Natl. Acad. Sci. USA 87, 3391-3395.
14. Quick, M. W., Naeve, J., Davidson, N. & Lester, H. A. (1992)
BioTechniques, in press.
15. Brecha, N. C., Sternini, C. & Humphrey, M. F. (1991) Cell.
Mol. Neurobiol. 11, 497-509.
16. Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman,
D. J. (1990) J. Mol. Biol. 215, 403-410.
17. Hutchison, H. T., Werrbach, K., Vance, C. & Haber, B. (1974)
Brain Res. 66, 265-274.
18. Schrier, B. K. & Thompson, E. J. (1974) J. Biol. Chem. 249,
1769-1780.
19. Erecinska, M., Troeger, M. B., Wilson, D. F. & Silver, I. A.
(1986) Brain Res. 369, 203-214.
20. Zafra, F. & Gimenez, C. (1986) Brain Res. 397, 108-116.
21. Zafra, F. & Gimenez, C. (1989) Biochem. J. 258, 403-408.
22. Schultz, S. G. & Curran, P. F. (1970) Physiol. Rev. 50, 637-710.
23. Johnston, G. A. R. & Iversen, L. L. (1971) J. Neurochem. 18,
1951-1961.
24. Staatz-Benson, C. & Potashner, S. J. (1987) J. Neurochem. 49,
128-137.
25. Debler, E. A. & Lajtha, A. (1987) J. Neurochem. 48,1851-1856.
26. Christensen, H. N. (1975) Curr. Top. Membr. Transp. 6, 227-
258.
27. Wilkin, G. P., Csillag, A., Balazs, R., Kingsbury, A. E., Wil-
son, J. E. & Johnson, A. L. (1981) Brain Res. 216, 11-33.
28. Ottersen, 0. P., Davanger, S. & Storm-Mathisen, J. (1987)
Exp. Brain Res. 66, 211-221.
29. Pourcho, R. G., Goegel, D. J., Jojich, L. & Hazlett, J. C.
(1992) Neuroscience 46, 643-656.
30. Halasz, N. & Shepherd, G. M. (1983) Neuroscience 10,579-619.
31. Smith, K. E., Borden, L. A., Hartig, P. R., Branchek, T. &
Weinshank, R. L. (1992) Neuron 8, 927-935.
Neurobiology: Guastefla et al.
